Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL.
Werner RA, Habacha B, Lütje S, Bundschuh L, Higuchi T, Hartrampf P, Serfling SE, Derlin T, Lapa C, Buck AK, Essler M, Pienta KJ, Eisenberger MA, Markowski MC, Shinehouse L, AbdAllah R, Salavati A, Lodge MA, Pomper MG, Gorin MA, Bundschuh RA, Rowe SP. Werner RA, et al. Among authors: salavati a. Mol Imaging. 2022 Feb 23;2022:7056983. doi: 10.1155/2022/7056983. eCollection 2022. Mol Imaging. 2022. PMID: 35283693 Free PMC article. Clinical Trial.
A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. Salavati A, et al. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4463-4471. doi: 10.1007/s00259-021-05415-y. Epub 2021 Jun 6. Eur J Nucl Med Mol Imaging. 2021. PMID: 34091713
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. Lawhn-Heath C, et al. Among authors: salavati a. Radiology. 2021 May;299(2):248-260. doi: 10.1148/radiol.2021202771. Epub 2021 Mar 30. Radiology. 2021. PMID: 33787338 Review.
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB 2nd, Siegel BA, Machtay M, Alavi A. Salavati A, et al. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1969-1983. doi: 10.1007/s00259-017-3753-x. Epub 2017 Jul 8. Eur J Nucl Med Mol Imaging. 2017. PMID: 28689281 Free PMC article. Clinical Trial.
An update on the role of PET/CT and PET/MRI in ovarian cancer.
Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, Werner TJ, Alavi A. Khiewvan B, et al. Among authors: salavati a. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1079-1091. doi: 10.1007/s00259-017-3638-z. Epub 2017 Feb 8. Eur J Nucl Med Mol Imaging. 2017. PMID: 28180966 Review.
104 results